Information  X 
Enter a valid email address

Benchmark Hlgs PLC (BMK)

  Print   

Tuesday 19 May, 2020

Benchmark Hlgs PLC

Notice of Q2 and Interim Results

RNS Number : 2687N
Benchmark Holdings PLC
19 May 2020
 

19 May 2020

 

Benchmark Holdings plc

 

("Benchmark" or the "Company")

 

 

Notice of Q2 and Interim Results

 

 

Benchmark Holdings plc (AIM: BMK), the aquaculture health, advanced nutrition, and genetics business, will announce its Q2 and Interim results for the three and six month periods ended 31 March 2020, on Friday 29 May 2020. 

 

Peter George, Executive Chairman, Septima Maguire, Chief Financial Officer, and Trond Williksen, incoming CEO, will host a webcast for analysts on that day at 9:30am. To register your interest, please contact [email protected] .

 

 

  Enquiries

For further information, please contact:


Benchmark Holdings plc

Tel:  020 3696 0630

Peter George, Executive Chairman


Septima Maguire, CFO


Ivonne Cantu, Investor Relations






Numis (Broker and NOMAD)

Tel:  020 7260 1000

James Black, Freddie Barnfield, Duncan Monteith

 




MHP Communications

Tel:  020 3128 8742

Katie Hunt, Reg Hoare, Alistair de Kare-Silver

[email protected]




 

About Benchmark

Benchmark's mission is to enable aquaculture food producers to improve their sustainability and profitability.

We develop innovative products which improve yield, quality and animal health and welfare for our customers. We do this by improving the genetic make-up, health and nutrition of their stock - from broodstock and hatchery through to nursery and grow out.

Benchmark has a broad portfolio of products and solutions, including salmon eggs, live feed (Artemia), diets and probiotics and sea lice treatments. Find out more at www.benchmarkplc.com

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NORAPMLTMTTBBPM

a d v e r t i s e m e n t